Evaluating the Immunogenicity and Safety of 9-valent Human Papillomavirus(Type6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine in Chinese Females Aged 9 to 45 Years: A Phase 3, Open-label, Non-randomised Clinical Trial
Latest Information Update: 22 Apr 2024
At a glance
- Drugs Human papillomavirus recombinant vaccine nonavalent - Shanghai Bovax Biotechnology (Primary)
- Indications Human papillomavirus infections
- Focus Pharmacodynamics; Registrational
- Sponsors Shanghai Bovax Biotechnology
- 23 Feb 2022 Planned primary completion date changed from 1 Dec 2021 to 1 May 2026.
- 02 Jun 2021 Status changed from not yet recruiting to recruiting.
- 25 May 2021 New trial record